188 related articles for article (PubMed ID: 31292251)
21. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
[TBL] [Abstract][Full Text] [Related]
22. Rotavirus vaccines: development and use for the prevention of diarrhoeal disease.
Vesikari T
Ann Med; 1999 Feb; 31(1):79-85. PubMed ID: 10219717
[TBL] [Abstract][Full Text] [Related]
23. Immunity and correlates of protection for rotavirus vaccines.
Franco MA; Angel J; Greenberg HB
Vaccine; 2006 Apr; 24(15):2718-31. PubMed ID: 16446014
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of oral Lanzhou lamb rotavirus vaccine via passive transfusion with CD4(+)/CD8(+) T lymphocytes.
Du J; Lan Z; Liu Y; Liu Y; Yu Q; Li Y; Guo T
Virus Res; 2016 Jun; 217():101-6. PubMed ID: 27025573
[TBL] [Abstract][Full Text] [Related]
25. The future control of rotavirus disease: Can live oral vaccines alone solve the rotavirus problem?
Glass RI; Jiang B; Parashar U
Vaccine; 2018 Apr; 36(17):2233-2236. PubMed ID: 29567032
[TBL] [Abstract][Full Text] [Related]
26. Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets.
Wang Y; Vlasova A; Velasquez DE; Saif LJ; Kandasamy S; Kochba E; Levin Y; Jiang B
PLoS One; 2016; 11(11):e0166038. PubMed ID: 27824918
[TBL] [Abstract][Full Text] [Related]
27. Intradermal and intranasal immunizations with oligomeric middle layer rotavirus VP6 induce Th1, Th2 and Th17 T cell subsets and CD4
Heinimäki S; Malm M; Vesikari T; Blazevic V
Antiviral Res; 2018 Sep; 157():1-8. PubMed ID: 29935205
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and efficacy in mice of an adenovirus-based bicistronic rotavirus vaccine expressing NSP4 and VP7.
Xie L; Yan M; Wang X; Ye J; Mi K; Yan S; Niu X; Li H; Sun M
Virus Res; 2015 Dec; 210():298-307. PubMed ID: 26368053
[TBL] [Abstract][Full Text] [Related]
29. The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses.
Saif LJ; Ward LA; Yuan L; Rosen BI; To TL
Arch Virol Suppl; 1996; 12():153-61. PubMed ID: 9015112
[TBL] [Abstract][Full Text] [Related]
30. Changing molecular epidemiology of rotavirus infection after introduction of monovalent rotavirus vaccination in Scotland.
Mukhopadhya I; Murdoch H; Berry S; Hunt A; Iturriza-Gomara M; Smith-Palmer A; Cameron JC; Hold GL
Vaccine; 2017 Jan; 35(1):156-163. PubMed ID: 27876201
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.
Bernstein DI; Glass RI; Rodgers G; Davidson BL; Sack DA
JAMA; 1995 Apr; 273(15):1191-6. PubMed ID: 7707626
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design.
Zhen SS; Li Y; Wang SM; Zhang XJ; Hao ZY; Chen Y; Wang D; Zhang YH; Zhang ZY; Ma JC; Zhou P; Zhang Z; Jiang ZW; Zhao YL; Wang XY
Emerg Microbes Infect; 2015 Oct; 4(10):e64. PubMed ID: 26576341
[TBL] [Abstract][Full Text] [Related]
33. A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia.
Beres LK; Tate JE; Njobvu L; Chibwe B; Rudd C; Guffey MB; Stringer JS; Parashar UD; Chilengi R
Clin Infect Dis; 2016 May; 62 Suppl 2():S175-82. PubMed ID: 27059353
[TBL] [Abstract][Full Text] [Related]
34. Lactobacillus rhamnosus GG Dosage Affects the Adjuvanticity and Protection Against Rotavirus Diarrhea in Gnotobiotic Pigs.
Wen K; Liu F; Li G; Bai M; Kocher J; Yang X; Wang H; Clark-Deener S; Yuan L
J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):834-43. PubMed ID: 25564808
[TBL] [Abstract][Full Text] [Related]
35. A TGF-beta mediated regulatory mechanism modulates the T cell immune response to rotavirus in adults but not in children.
Mesa MC; Gutiérrez L; Duarte-Rey C; Angel J; Franco MA
Virology; 2010 Mar; 399(1):77-86. PubMed ID: 20096911
[TBL] [Abstract][Full Text] [Related]
36. Developing an Inactivated Rotavirus Vaccine and Evaluating the Immunogenicity Against a Commercially Available Attenuated Rotavirus Vaccine Using a Mice Animal Model.
Hashim AS; Aboshanab KM; El-Sayed AF
Viral Immunol; 2016 Dec; 29(10):565-571. PubMed ID: 27860553
[TBL] [Abstract][Full Text] [Related]
37. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance.
Chung Y; Lee SH; Kim DH; Kang CY
J Leukoc Biol; 2005 Jun; 77(6):906-13. PubMed ID: 15758078
[TBL] [Abstract][Full Text] [Related]
38. Clinical and immunological studies of rotavirus vaccines.
Vesikari T
Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):437-47. PubMed ID: 2851185
[TBL] [Abstract][Full Text] [Related]
39. Oral rotavirus vaccine shedding as a marker of mucosal immunity.
Lee B; Kader MA; Colgate ER; Carmolli M; Dickson DM; Diehl SA; Alam M; Afreen S; Mychaleckyj JC; Nayak U; Petri WA; Haque R; Kirkpatrick BD
Sci Rep; 2021 Nov; 11(1):21760. PubMed ID: 34741103
[TBL] [Abstract][Full Text] [Related]
40. Development of candidate rotavirus vaccines derived from neonatal strains in India.
Glass RI; Bhan MK; Ray P; Bahl R; Parashar UD; Greenberg H; Rao CD; Bhandari N; Maldonado Y; Ward RL; Bernstein DI; Gentsch JR
J Infect Dis; 2005 Sep; 192 Suppl 1():S30-5. PubMed ID: 16088802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
